Last reviewed · How we verify
GT90001 and Nivolumab
GT90001 and Nivolumab is a Small molecule drug developed by Suzhou Kintor Pharmaceutical Inc,. It is currently in Phase 1 development. Also known as: GT90001 and Opdivo.
At a glance
| Generic name | GT90001 and Nivolumab |
|---|---|
| Also known as | GT90001 and Opdivo |
| Sponsor | Suzhou Kintor Pharmaceutical Inc, |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- GT90001 Plus Nivolumab in Patients With Advanced Hepatocellular Carcinoma (PHASE2)
- Combination of GT90001 and Nivolumab in Patients With Metastatic Hepatocellular Carcinoma(HCC) (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GT90001 and Nivolumab CI brief — competitive landscape report
- GT90001 and Nivolumab updates RSS · CI watch RSS
- Suzhou Kintor Pharmaceutical Inc, portfolio CI
Frequently asked questions about GT90001 and Nivolumab
What is GT90001 and Nivolumab?
GT90001 and Nivolumab is a Small molecule drug developed by Suzhou Kintor Pharmaceutical Inc,.
Who makes GT90001 and Nivolumab?
GT90001 and Nivolumab is developed by Suzhou Kintor Pharmaceutical Inc, (see full Suzhou Kintor Pharmaceutical Inc, pipeline at /company/suzhou-kintor-pharmaceutical-inc).
Is GT90001 and Nivolumab also known as anything else?
GT90001 and Nivolumab is also known as GT90001 and Opdivo.
What development phase is GT90001 and Nivolumab in?
GT90001 and Nivolumab is in Phase 1.
Related
- Manufacturer: Suzhou Kintor Pharmaceutical Inc, — full pipeline
- Also known as: GT90001 and Opdivo
- Compare: GT90001 and Nivolumab vs similar drugs
- Pricing: GT90001 and Nivolumab cost, discount & access